MRNA vs PFE: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

PFE is the larger of the two ($176.05B market cap): the incumbent the market prices for continued execution (10.70x forward earnings, beta 0.30). MRNA is the smaller challenger ($89.16B), priced similarly on forward earnings (-48.70x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

MRNA vs PFE: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricMRNAPFEWhat it tells you
Market cap$89.16B$176.05BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-48.7010.70Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.170.30Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range87% of range99% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book13.182.07How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how MRNA and PFE affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MRNA and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MRNA and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Moderna (MRNA) do?

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

Full MRNA guide

What does Pfizer (PFE) do?

Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.

Full PFE guide

MRNA vs PFE: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.
  • PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.

MRNA or PFE: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MRNA if you believe its drivers more; PFE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MRNA and PFE guides.

MRNA vs PFE: the full fundamentals

MRNA. MRNA trades on pipeline potential rather than current earnings: it is loss-making, revenue is far below its pandemic peak, and P/E is not meaningful. What changed in 2026 is the price of that option, with the stock up about 590% year to date to roughly 38 times trailing sales after the August Phase 3 melanoma success. The 18 analysts Yahoo Finance tracks have a mean target near $124, well under the $213 close, so the detailed data later in October and the November 6 Q3 report (consensus revenue near $892 million, EPS near -$1.30) carry unusual weight.

PFE. Pfizer trades at about 10x forward earnings and a dividend yield near 5.8%, a below-market multiple that reflects investor concern about the post-COVID revenue reset and a looming patent cliff. The gap between a trailing GAAP P/E near 39x and the forward figure comes from large GAAP charges rather than weak operations. Even after a 17.5% gain in 2026 the shares sit right around the 26 analysts' mean target of about $29, so the valuation now balances substantial cash generation against flat-to-lower consensus earnings.

Headline figures (approximate, October 2026): MRNA shows market cap ~$85 billion, revenue (ttm) ~$2.2 billion, q2 2026 revenue ~$145 million, net income (ttm) ~-$3.2 billion; PFE shows revenue (ttm) ~$63.7 billion (Q2 2026 +~2.6% YoY), operating margin ~28%, net income (ttm, gaap) ~$4.3 billion, q2 2026 adjusted eps ~$0.77 vs ~$0.68 consensus.

The bottom line: MRNA vs PFE

MRNA and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MRNA and PFE exposure against your real portfolio. It is not an investment adviser.

Wondering how MRNA or PFE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Investing in Moderna with AI

Connect the broker you already use and ask Walnut's AI how MRNA fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

FAQ

What is the difference between MRNA and PFE?

+

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is MRNA or PFE the better stock?

+

Neither is universally better. PFE is the larger incumbent; MRNA is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, MRNA or PFE?

+

On forward P/E (as of November 2026), MRNA trades at -48.70x and PFE at 10.70x, so MRNA is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both MRNA and PFE?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of MRNA vs PFE?

+

MRNA: Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. The company is loss-making and burning cash, making it dependent on pipeline approvals landing on schedule. Regulatory risk is concrete: the FDA issued a Refusal-to-File letter for the flu vaccine earlier in 2026, and shifting U.S. vaccine policy adds uncertainty. Large legal settlements (such as the Arbutus and Genevant charge) can swing reported results, and much of the long-term value depends on the Merck-partnered cancer vaccine succeeding in Phase 3, which is far from guaranteed. Valuation risk is now acute: at about $85 billion the company trades near 38 times trailing sales, analysts are split (Goldman Sachs raised its target to $137 with a Neutral rating, Morgan Stanley is at $95, Citi has a Sell and an $80 target, all below the October 16 price), and the stock fell about 9% in a single day on October 16 as profit-taking set in. A disappointing detailed readout of the melanoma data could reverse much of the gain. Walnut is not an investment adviser. PFE: Pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap. Analysts' consensus as of October 2026 has revenue slipping to about $62.2 billion in 2026 and $59.9 billion in 2027, with EPS of roughly $2.96 and $2.89, so earnings are expected to drift lower rather than grow. COVID-19 product revenue (Comirnaty, Paxlovid) has fallen sharply and remains volatile and hard to forecast. The Seagen deal added substantial debt (total debt is about $63.5 billion against $11.7 billion of cash), and large acquisitions carry integration and return risk. The dividend exceeds GAAP earnings (a payout above 200% on trailing GAAP EPS), so it leans on adjusted earnings and cash flow. Drug pricing pressure, including US policy such as Medicare negotiation, threatens margins on key products. Pipeline setbacks, clinical-trial failures, and regulatory decisions can swing the stock, and the company must continually prove it can generate new blockbusters to sustain growth as legacy drugs mature.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell MRNA or PFE; figures are approximate and dated (as of November 2026). Verify current data before investing.